Novozymes A/S (OTCMKTS:NVZMY) Raised to Strong-Buy at Barclays

Barclays upgraded shares of Novozymes A/S (OTCMKTS:NVZMY) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Several other equities research analysts have also commented on NVZMY. Citigroup lowered Novozymes A/S from a “neutral” rating to a “sell” rating in a research report on Thursday, October 17th. Berenberg Bank raised Novozymes A/S to a “strong-buy” rating in a research note on Tuesday, September 24th.

Novozymes A/S Stock Up 0.3 %

Shares of NVZMY opened at $57.46 on Monday. The business has a 50-day simple moving average of $65.40 and a two-hundred day simple moving average of $63.78. Novozymes A/S has a 12-month low of $49.99 and a 12-month high of $72.50. The stock has a market cap of $26.91 billion, a PE ratio of 36.37, a PEG ratio of 3.87 and a beta of 0.90.

Novozymes A/S Cuts Dividend

The business also recently announced a dividend, which was paid on Wednesday, September 18th. Shareholders of record on Monday, September 9th were given a dividend of $0.1678 per share. The ex-dividend date of this dividend was Monday, September 9th. Novozymes A/S’s payout ratio is presently 41.77%.

Novozymes A/S Company Profile

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.